Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration

BMC Ophthalmology

Volumn 7, Issue , 2007, Pages

  Ahmadieh, Hamid ^a   Taei, Ramin ^a   Soheilian, Masoud ^a   Riazi Esfahani, Mohammad ^b,c   Karkhaneh, Reza ^b   Lashay, Alireza ^b   Azarmina, Mohsen ^a   Dehghan, Mohammad Hossein ^a   Moradian, Siamak ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c NOOR EYE HOSPITAL   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIGLAUCOMA AGENT; BENZOPORPHYRIN DERIVATIVE; BEVACIZUMAB; DORZOLAMIDE; TIMOLOL; TRIAMCINOLONE ACETONIDE; TRIAMHEXAL; UNCLASSIFIED DRUG; ANGIOGENESIS INHIBITOR; GLUCOCORTICOID; MONOCLONAL ANTIBODY; TRIAMCINOLONE;

ADULT; AGED; ARTICLE; CASE STUDY; CHOROID; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG PULSE THERAPY; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; INTERVENTION STUDY; INTRAOCULAR HYPERTENSION; MAINTENANCE THERAPY; MALE; OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY; PROSPECTIVE STUDY; REPEATED DRUG DOSE; RETINA FOVEA; RETINA MACULA AGE RELATED DEGENERATION; STATISTICAL SIGNIFICANCE; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; VISUAL ACUITY; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECT; INJECTION; MIDDLE AGED; PATHOPHYSIOLOGY; PHOTOCHEMOTHERAPY; RETINA MACULA DEGENERATION; VITREOUS BODY;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; INJECTIONS; MACULAR DEGENERATION; MALE; MIDDLE AGED; PHOTOCHEMOTHERAPY; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TRIAMCINOLONE; VISUAL ACUITY; VITREOUS BODY;

EID: 34347390080     PISSN: None     EISSN: 14712415     Source Type: Journal    
DOI: 10.1186/1471-2415-7-10     Document Type: Article

References (27)

1. Photodynamic therapy of subfoveal choroidal neovascularization in age- related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials- TAP report 1. Treatment of Age- Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group, Arch Ophthalmol 1999 117 1329 1345 10532441
2. Photodynamic therapy of subfoveal choroidal neovascularization in age- related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials- TAP report 2. Treatment of Age- Related Macular Degeneration with Photodynamic Therapy (TAP)Study Group, Arch Ophthalmol 2001 119 198 207 11176980
3. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two- year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization- Verteporfin in Photodynamic Therapy Report 2. Verteporfin in Photodynamic Therapy (VIP) Study Group, Am J Ophthalmol 2001 131 541 560 10.1016/S0002-9394(01)00967-9 11336929
4. Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes. U Schlotzer-Schrehardt A Viestenz GO Naumann H Laqua S Michels U Schmidt-Erfurth, Graefes Arch Clin Exp Ophthalmol 2002 240 748 757 12271373
5. Photodynamic effects on choroidal neovascularization and physiological choroid. U Schmidt-Erfurth S Michels I Barbazetto H Laqua, Invest Ophthalmol Vis Sci 2002 43 830 841 11867605
6. Sequence of early vascular events after photodynamic therapy. S Michels U Schmidt-Erfurth, Invest Ophthalmol Vis Sci 2003 44 2147 2154 10.1167/iovs.02-0604 12714655
7. Time course and morphology of vascular effects associated with photodynamic therapy. U Schmidt-Erfurth M Niemeyer W Geitzenauer S Michels, Ophthalmology 2005 112 2061 2069 10.1016/j.ophtha.2005.09.007 16325705
8. Inhibitory effects of triamcinolone acetonide on bFGF - induced migration and tube formation in choroidal microvascular endothelial cells. YS Wang U Friedrichs W Eichler S Hoffmann P Wiedemann, Graefes Arch Clin Exp Ophthalmol 2002 240 42 48 11954780
9. Intravitreal triamcinolone acetonide in exudative age- related macular degeneration. RP Danis TA Ciulla LM Pratt W Anliker, Retina 2000 20 244 250 10.1097/00006982-200005000-00003 10872928
10. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. MC Gillies JM Simpson W Luo P Penfold AB Hunyor W Chua P Mitchell F Billson, Arch Ophthalmol 2003 121 667 673 10.1001/archopht.121.5.667 12742844
11. Intravitreal reinjection of triamcinolone for exudative age-related macular degeneration. JB Jonas I Akkoyun WM Budde I Kreissig RF Degenring, Arch Ophthalmol 2004 122 218 222 10.1001/archopht.122.2.218 14769599
12. Intravitreal triamcinolone reinjection for refractory diabetic macular edema. AR Ramezani H Ahmadieh H Tabatabaie, Korean J Ophthalmol 2006 20 156 161 17004629
13. Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularization in age related macular degeneration. E Rechtman RP Danis LM Pratt A Haries, Br J Ophthalmol 2004 88 344 347 10.1136/bjo.2003.027177 14977766
14. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. RF Spaide J Sorenson L Maranan, Ophthalmology 2005 112 301 304 10.1016/j.ophtha.2004.08. 012 15691567
15. Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration. AJ Augustin U Schmidt-Erfurth, Ophthalmology 2006 113 14 21 10.1016/j.ophtha.2005. 09.002 16360209
16. Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidal neovascularization in age- related macular degeneration. AJ Augustin U Schmidt-Erfurth, Am J Ophthalmol 2006 141 638 645 10.1016/j.ajo.2005.11.058 16564797
17. Photodynamic therapy and high-dose intravitreal triamcinolone to treat exudative age-related macular degeneration. JMA Ruiz-Moreno JA Montero S Barile MA Zarbin, Retina 2006 26 602 612 10.1097/00006982-200607000-00003 16829800
18. Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of subfoveal choroidal neovascularization in age related macular degeneration: a comparative study. WM Chan TYY Lai AL Wong JP Tong DTL Liu DSC Lam, Br J Ophthalmol 2006 90 337 341 10.1136/bjo.2005.081299 16488958
19. Intravitreal bevacizumab (Avastin) for neovascular age- related macular degeneration. RL Avery DJ Pieramici MD Rabena AA Castellarin MA Nasir MJ Giust, Ophthalmology 2006 113 363 372 10.1016/j.ophtha.2005.11.019 16458968
20. Photodynamic therapy with verteporfin combined with intravitreal injection of bevacizumab for exudative age-related macular degeneration. FB Aggio GB Melo AL Hofling-Lima ME Farah, Acta Ophthalmologica Scandinavica 2006 84 831 833 10.1111/j.1600-0420.2006.00764.x 17083553
21. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. MS Dhalla GK Shah KJ Blinder EH Ryan Jr RA Mittra A Tewari, Retina 2006 26 988 993 10.1097/01.iae.0000247164.70376.91 17151484
22. Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study). RA Costa R Jorge D Calucci LA Melo Jr JA Cardillo IU Scott, Greafes Arch Clin Exp Ophthalmol 2007, Feb 28: DOI 10.1007/s00417-007-0557-x
23. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. AJ Augustin S Puls I Offermann, Retina 2007 27 133 140 10.1097/IAE.0b013e3180323de7 17290193
24. Problems with and pitfalls of photodynamic therapy. GA Peyman AA Kazi M Unal B Khoobehi S Yoneya K Mori DM Moshfeghi, Ophthalmology 2000 107 29 35 10.1016/S0161-6420(99)00012-3 10647715
25. Verteporfin photodynamic therapy retreatment of normal retina and choroid in the cynomolgus monkey. MH Reinke C Canakis D Husain N Michaud TJ Flotte ES Gragoudas JW Miller, Ophthalmology 1999 106 1915 1923 10.1016/S0161-6420(99) 90401-3 10519585
26. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium - derived factor. U Schmidt-Erfurth U Schlotzer-Schrehardt C Cursiefen S Michels A Beckendorf GO Naumann, Invest Ophthalmol Vis Sci 2003 44 4473 4480 10.1167/iovs.02-1115 14507895
27. Triamcinolone acetonide suppresses early proangiogenic response in RPE cells after photodynamic therapy in vitro. R Obata Yuji Inoue A Iriyama H Takahashi Y Tamaki Y Yanagi, Br J Ophthalmol 2007 91 100 104 10.1136/bjo.2006.098004 16987905